Editorial

DOI: 10.4244/EIJ-E-25-00008

Platelet reactivity when switching from cangrelor to oral P2Y12 receptor inhibitors: insights from a real-world registry

Francesco Franchi1, MD; Claudio Laudani1,2, MD, MSc

Dual antiplatelet therapy with aspirin and a P2Y12 receptor inhibitor (P2Y12-i) is the standard of care for patients undergoing percutaneous coronary intervention (PCI)1. However, in high-risk settings, such as patients with acute coronary syndrome (ACS), the onset of action of an oral P2Y12-i, including the more potent prasugrel and ticagrelor, can be delayed, leaving a gap in platelet inhibition up to 4-6 hours after PCI. Cangrelor, the only currently available intravenous P2Y12-i, is characterised by high antiplatelet potency and fast onset and offset of action, making it a viable option in patients undergoing PCI who require immediate and potent platelet inhibition2. In clinical trials, cangrelor has been shown to reduce thrombotic events in patients undergoing PCI when used in addition to clopidogrel3. However, in real-world practice, prasugrel and ticagrelor are more commonly used among cangrelor-treated patients. Although most pharmacodynamic (PD) studies have shown that cangrelor is able to provide additional platelet inhibition when used along with prasugrel and ticagrelor in various clinical settings456, one study has suggested high residual platelet reactivity (HRPR) in patients...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 10
May 16, 2025
Volume 21 Number 10
View full issue


Key metrics

Suggested by Cory

Research correspondence

10.4244/EIJ-D-22-00594 Mar 20, 2023
Pharmacodynamic effects of cangrelor in elective complex PCI: insights from the POMPEII Registry
Gargiulo G et al
free

Debate

10.4244/EIJ-E-23-00070 Apr 1, 2024
Guideline recommendations for cangrelor should be upgraded: pros and cons
Dangas G et al
free

Editorial

10.4244/EIJ-E-23-00003 Mar 20, 2023
Clopidogrel: still king of the ring for elective percutaneous coronary intervention!
Montalescot G and Ferrante A
free
Trending articles
309.93

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
166.7

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
92.2

State-of-the-Art Review

10.4244/EIJ-D-20-01296 Aug 27, 2021
Management of cardiogenic shock
Thiele H et al
free
76

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
72.85

State-of-the-Art

10.4244/EIJ-D-24-00386 Feb 3, 2025
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Ferro E et al
free
58.3

Clinical research

10.4244/EIJ-D-23-00344 Sep 18, 2023
Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
Sanchez-Luna JP et al
free
56.65

Clinical research

10.4244/EIJ-D-20-01155 Oct 20, 2021
A deep learning algorithm for detecting acute myocardial infarction
Liu W et al
free
33.9

CLINICAL RESEARCH

10.4244/EIJ-D-17-00381 Oct 11, 2017
Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model
Foin N et al
free
33.65

State-of-the-Art

10.4244/EIJ-D-23-00606 Jan 1, 2024
Targeting inflammation in atherosclerosis: overview, strategy and directions
Waksman R et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved